Pacira BioSciences, Inc. (PCRX)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Total revenues | 181,099 | 168,923 | 168,573 | 178,023 |
| Goodwill impairment | - | - | 163,243 | - |
| Contingent consideration (gains) charges, restructuring charges and other | - | - | 1,766 | -2,735 |
| Selling, general and administrative | 88,578 | 86,776 | 74,333 | 68,126 |
| Research and development | 28,200 | 25,342 | 19,104 | 20,338 |
| Cost of goods sold | 40,866 | 34,306 | 38,864 | 44,262 |
| Amortization of acquired intangible assets | 14,322 | 14,322 | 14,322 | 14,322 |
| Total contingent consideration (gains) charges, acquisition-related expenses, restructuring and other | 634 | 6,187 | - | - |
| Total operating expenses | 172,600 | 166,933 | 308,100 | 149,783 |
| Income from operations | 8,499 | 1,990 | -139,527 | 28,240 |
| Other, net | -10,739 | 4,401 | -122 | -39 |
| Interest income | 5,008 | 6,895 | 5,482 | 4,749 |
| Interest expense | 4,695 | 4,580 | 4,689 | 3,884 |
| Gain on early extinguishment of debt | - | - | - | 7,518 |
| Total other (expense) income, net | -10,426 | 6,716 | 671 | 8,344 |
| (loss) income before income taxes | -1,927 | 8,706 | -138,856 | 36,584 |
| Income tax expense | 2,920 | 3,894 | 4,610 | 17,698 |
| Net (loss) income | -4,847 | 4,812 | -143,466 | 18,886 |
| Basic (in shares) | 45,459,000 | 46,275,000 | 46,134,000 | 46,174,000 |
| Basic net (loss) income per common share (in dollars per share) | -0.11 | 0.1 | -3.11 | 0.41 |
| Diluted (in shares) | 45,459,000 | 46,526,000 | 46,134,000 | 50,539,000 |
| Diluted net (loss) income per common share (in dollars per share) | -0.11 | 0.1 | -3.11 | 0.39 |